Insider Sell: Gael Touya Sells 3,500 Shares of AptarGroup Inc (ATR)
Gael Touya, Segment President at AptarGroup Inc (ATR), sold 3,500 shares of the company on February 18, 2026, bringing his total holdings to 27,963 shares. Over the past year, there have been 0 insider buys and 14 insider sells at AptarGroup. The stock is currently trading at $141.35 and is considered fairly valued based on its GF Value.
Aptar CEO and CFO head to 2026 investor talks in late Feb and March
AptarGroup, Inc. (NYSE: ATR) announced its CEO, Stephan Tanda, will present at the Bank of America Securities 2026 Global Agriculture and Materials Conference on February 25, 2026. Executive Vice President and CFO, Vanessa Kanu, will present at the Raymond James 2026 Institutional Investors Conference on March 3, 2026. Live audio webcasts and presentation materials for both events will be available on the company's investor relations website.
Aptar to Participate in Upcoming Investor Conferences
AptarGroup, Inc. (NYSE: ATR) announced its participation in two upcoming investor conferences: the Bank of America Securities 2026 Global Agriculture and Materials Conference and the Raymond James 2026 Institutional Investors Conference. Stephan Tanda, President and CEO, and Vanessa Kanu, EVP and CFO, will present at these events, respectively. Live audio webcasts and presentation materials will be available on the company's website.
Here’s What Makes AptarGroup (ATR) a Long-Term Holding
Aristotle Capital Boston, LLC added AptarGroup, Inc. (NYSE:ATR) to its portfolio, highlighting the company's role as a global packaging company specializing in dosing, dispensing, and protection technologies for various industries. The fund believes AptarGroup is well-positioned for long-term shareholder value creation due to a cyclical rebound in demand and investments in its pharmaceutical division. Despite positive outlook, the article notes that 29 hedge funds held the stock, with the Q4 2025 sales increasing by 14% to $963 million.
Hantz Financial Services Inc. Sells 53,831 Shares of AptarGroup, Inc. $ATR
Hantz Financial Services Inc. significantly reduced its stake in AptarGroup, Inc. (NYSE:ATR) by selling 53,831 shares, leaving it with only 408 shares. This comes as AptarGroup reported slightly better-than-expected quarterly earnings, announced a $600 million stock repurchase program, and saw mixed activity from other institutional investors and analysts. ATR's chief accounting officer also sold a notable portion of his holdings.
Envestnet Asset Management Inc. Has $25.79 Million Stock Position in AptarGroup, Inc. $ATR
Envestnet Asset Management Inc. recently reduced its stake in AptarGroup, Inc. by 12.5% in Q3, holding 192,919 shares valued at $25.79 million. AptarGroup reported strong quarterly results, beating EPS and revenue expectations, and announced a $600 million share buyback program and a quarterly dividend of $0.48 per share. Insider activity also noted, with CAO Daniel Ackerman selling 15,000 shares.
AptarGroup Shares Navigate Divergent Signals from Insiders and Institutions
AptarGroup (ATR) is presenting a complex financial picture, with robust revenue growth but declining net income in Q4 2025. The company's stock activity shows divergent signals as a Segment President sold shares, while Morgan Stanley solidified its significant institutional holding. AptarGroup also announced a new share repurchase program and a quarterly dividend, with management providing an optimistic EPS forecast for Q1 2026.
Insider Sell: Marc Prieur Sells 2,000 Shares of AptarGroup Inc (ATR)
Marc Prieur, Segment President at AptarGroup Inc (ATR), sold 2,000 shares of the company on February 10, 2026, reducing his holding to 13,745 shares. This sale is part of a pattern, as Prieur has sold 10,000 shares over the past year with no purchases. AptarGroup Inc's stock is currently considered fairly valued, trading at $137.81, with a price-to-GF-Value ratio of 0.92, and its P/E ratio of 23.70 is lower than the industry median.
Aptargroup segment president Prieur sells $275k in stock
Aptargroup Segment President Marc Prieur sold 2,000 shares of common stock for $275,620 on February 10, 2026. Following this transaction, Prieur now directly owns 13,745 shares of Aptargroup stock. This sale occurred shortly after AptarGroup Inc. reported strong fourth-quarter 2025 earnings, exceeding Wall Street's EPS and revenue expectations.
AptarGroup, Inc. (NYSE:ATR) Given Average Recommendation of "Hold" by Brokerages
AptarGroup, Inc. (NYSE:ATR) has received an average "Hold" recommendation from brokerages, based on ratings from seven analysts. The company reported a Q-quarter EPS of $1.25, surpassing estimates, and revenue of $962.74M, up 13.5% year-over-year. AptarGroup also announced a $600 million stock buyback program and a quarterly dividend of $0.48 per share.
Despite Emergency Medicines Destocking, Aptar's Underlying Business Remains Healthy
Aptar, a global leader in dispensing technologies, maintains a healthy underlying business despite destocking of emergency medicines. The company focuses on its profitable healthcare segment, which generates about two-thirds of its operating profits, while also operating in beauty and closures segments. Morningstar reiterates its $274 fair value estimate for AptarGroup Inc.
AptarGroup, Inc. (ATR) Shares Rise on Q4 Revenue Beat Amid Margin Pressure
AptarGroup (ATR) shares saw a modest increase after reporting Q4 and full-year 2025 results, with Q4 sales of $963 million surpassing estimates. Despite a revenue beat and strong performance in the Pharma segment, the company faced margin pressures from product mix and operational costs in the Beauty and Closures segments. Aptar provided Q1 2026 adjusted EPS guidance between $1.13 and $1.21 and outlined strategic focus areas including high-return pharma projects and productivity gains.
AptarGroup, Inc. (NYSE:ATR) Q4 2025 Earnings Call Transcript
AptarGroup, Inc. reported strong Q4 2025 sales, growing 14% to $963 million, with core sales up 5% despite operational challenges in Beauty and Closures and a decline in emergency medicine demand. The company emphasized its robust Pharma pipeline, especially in systemic nasal drug delivery and injectables, and highlighted several new product launches and FDA approvals. Aptar Group also maintained its commitment to shareholder returns, announcing a new $600 million share repurchase authorization and continuing its annually increasing dividend for the 32nd consecutive year.
AptarGroup declares $0.48 dividend
NULL
APTARGROUP, INC. SEC 10-K Report
AptarGroup, Inc. has released its 2025 10-K report, detailing a 5% increase in net sales to $3,777.2 million and a 7% increase in diluted EPS to $5.89. The company highlighted strong growth in its Pharma segment, strategic acquisitions, and capital management efforts, while acknowledging challenges such as market competition, economic uncertainties, and rising raw material costs. AptarGroup plans to continue focusing on organic growth, strategic investments, and sustainability.
Earnings call transcript: AptarGroup Q4 2025 earnings beat expectations, stock surges
AptarGroup Inc. reported better-than-expected Q4 2025 earnings with an EPS of $1.25 and revenue of $963 million, leading to a 7.5% stock surge. The company saw strong performance in its pharma and beauty segments, driven by new product innovations, despite operational challenges in beauty enclosures. AptarGroup anticipates continued growth, particularly in emergency medicine, and reaffirmed its commitment to shareholder returns and strategic investments.
How Strong Q4 Results and FX-Tied Guidance Will Impact AptarGroup (ATR) Investors
AptarGroup, Inc. reported stronger-than-expected fourth-quarter results, exceeding analyst forecasts with adjusted earnings of US$1.25 per share and revenue of US$962.70 million. The company's first-quarter 2026 guidance, explicitly tied to a 1.18 EUR-to-US$ exchange rate, highlights the increasing impact of currency fluctuations on its financial performance and investment narrative. Despite its shares potentially being undervalued, managing foreign exchange exposure will be crucial for AptarGroup's continued earnings reliability and dividend record.
How Strong Q4 Results and FX-Tied Guidance Will Impact AptarGroup (ATR) Investors
AptarGroup (ATR) reported strong Q4 results, exceeding analyst forecasts, and issued Q1 2026 earnings guidance tied to a specific EUR-to-USD exchange rate. This highlights the increasing importance of foreign exchange sensitivity in assessing the company's performance, even as its shares remain potentially undervalued. Investors should consider how currency swings could affect AptarGroup's earnings stability and its ability to maintain its dividend record.
Aptar Reports Fourth Quarter and Annual 2025 Results
AptarGroup, Inc. reported its fourth quarter and annual results for 2025, showing increased sales across all segments driven by strong demand in Pharma and Beauty, despite a decrease in reported net income for Q4. The company delivered 5% reported sales growth and 2% core sales growth annually, maintaining its 32nd consecutive year of increasing dividends. Aptar also announced a new $600 million share repurchase authorization.
AptarGroup Inc (NYSE:ATR) Beats Q4 Revenue Estimates, Issues Cautious Q1 Outlook
AptarGroup Inc (NYSE:ATR) reported strong Q4 2025 revenues that surpassed analyst expectations, driven by growth across all segments, especially injectables and beauty. However, profitability was impacted by higher production costs and operational disruptions, leading to a cautious adjusted EPS outlook for Q1 2026. Despite the mixed results, the company maintained a solid financial position and authorized a new $600 million share repurchase program, reassuring investors of continued capital returns.
AptarGroup: Q4 Earnings Snapshot
AptarGroup Inc. reported strong fourth-quarter earnings, exceeding Wall Street expectations with $74.3 million in net income and $1.25 adjusted earnings per share. The company also surpassed revenue forecasts, recording $962.7 million for the period. For the upcoming quarter, AptarGroup projects earnings per share between $1.13 and $1.21.
AptarGroup (ATR) Releases Q4 2025 Earnings: Revenue Growth but EPS Miss
AptarGroup (ATR) reported Q4 2025 revenues of $962.7 million, exceeding analyst estimates, but missed EPS targets with $1.13 per share. The company experienced strong revenue growth and healthy cash generation, yet saw declines in operating profit and net income due to increased cost of sales. Insider sales and mixed institutional investor activity were also noted.
AptarGroup, Inc. Reports Fourth Quarter and Annual 2025 Results
AptarGroup, Inc. reported its financial results for the fourth quarter and full year ending December 31, 2025, showing significant sales growth but a decrease in net income for Q4. The company's sales increased by 14% in Q4 to $963 million, with annual sales reaching $3.78 billion. All segments achieved core sales growth, and AptarGroup plans further share repurchases and anticipates strong performance in its Pharma and Beauty segments for 2026.
Aptar Reports Fourth Quarter and Annual 2025 Results
AptarGroup, Inc. (NYSE:ATR) reported its fourth quarter and annual 2025 results, highlighting a 14% increase in reported sales and 5% core sales growth for the fourth quarter, with all three segments contributing. For the full year, reported sales rose 5% and core sales increased 2%. The company returned $486 million to shareholders in 2025 through share repurchases and dividends and has authorized a new share repurchase program of up to $600 million.
AptarGroup Inc. Reveals Drop In Q4 Income
AptarGroup Inc. reported a significant drop in its fourth-quarter profit, with net income falling to $74.34 million, or $1.13 per share, compared to $100.94 million, or $1.49 per share, in the previous year. Despite the profit decline, the company's revenue increased by 13.5% to $962.73 million. AptarGroup also provided guidance for the next quarter's EPS, ranging from $1.13 to $1.21.
AptarGroup, Inc. $ATR Shares Sold by Bridges Investment Management Inc.
Bridges Investment Management Inc. significantly reduced its stake in AptarGroup, Inc. (NYSE:ATR) by 27.8% in Q3, selling over 10,000 shares. Additionally, CAO Daniel Ackerman completed an insider sale of 15,000 shares, decreasing his ownership by over 33%. Despite these sales, AptarGroup announced a quarterly dividend of $0.48 per share, while analysts maintain a "Hold" average rating with an average target price of $167.50.
Strs Ohio Reduces Stake in AptarGroup, Inc. $ATR
Strs Ohio significantly reduced its stake in AptarGroup, Inc. (NYSE:ATR) by 90.6% in the third quarter of 2025, selling 15,100 shares and ending with 1,564 shares valued at $209,000. Despite this reduction, other large institutional investors like Norges Bank, AQR Capital Management, Ameriprise Financial, Mawer Investment Management, and Boston Trust Walden Corp increased their holdings, leading to institutional investors owning 88.52% of the company. AptarGroup also declared a quarterly dividend of $0.48, and analysts currently have a "Hold" rating on the stock with a consensus price target of $167.50.
Earnings Preview: AptarGroup (ATR) Q4 Earnings Expected to Decline
AptarGroup (ATR) is projected to report a year-over-year decline in Q4 earnings despite higher revenues. The company's EPS is expected to be $1.24, down 18.4%, while revenues are anticipated to climb 5.7% to $896.66 million. The Zacks Earnings ESP indicates a potential earnings miss for AptarGroup, which could impact its stock price.
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
AptarGroup, Inc. (NYSE: ATR) announced a quarterly cash dividend of $0.48 per share, payable on February 25, 2026, to shareholders of record as of February 4, 2026. The company also confirmed that its 2026 Annual Meeting of Stockholders will be held virtually on May 6, 2026, at 9:00 a.m. Central Time, with a record date of March 13, 2026, for voting eligibility.
AptarGroup declares $0.48 quarterly dividend, sets annual meeting By Investing.com
AptarGroup, Inc. has announced a quarterly cash dividend of $0.48 per share, continuing its 33-year streak of dividend payments. The company also scheduled its 2026 Annual Meeting of Stockholders for May 6, 2026, and will discuss its fourth-quarter and year-end 2025 results on February 6, 2026. This news follows recent developments in its healthcare sector, including its nasal delivery solutions being used in a COVID-19 vaccine trial and its Bidose Liquid Nasal Spray System for a new PSVT treatment.
AptarGroup Keeps Quarterly Dividend at $0.48 a Share, Payable Feb. 25 to Shareholders of Record on Feb. 4
AptarGroup announced it will maintain its quarterly dividend at $0.48 per share. The dividend is scheduled to be paid on February 25 to shareholders of record as of February 4. This information indicates the company's consistent dividend policy.
AptarGroup declares $0.48 dividend
AptarGroup has declared a quarterly dividend of $0.48 per share. This dividend is payable on February 20, 2026, to shareholders of record as of February 6, 2026. This announcement highlights the company's commitment to returning value to its shareholders.
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
AptarGroup, Inc. has announced a quarterly cash dividend of $0.48 per share, payable on February 25, 2026, to stockholders of record as of February 4, 2026. The company also declared that its 2026 Annual Meeting of Stockholders will be held virtually on May 6, 2026, with a record date for voting stockholders set for March 13, 2026. Additionally, Aptar will host a conference call on February 6, 2026, to discuss its fourth-quarter and year-end 2025 results.
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
AptarGroup, Inc. has announced a quarterly cash dividend of $0.48 per share, payable on February 25, 2026, to stockholders of record as of February 4, 2026. The company will also hold its 2026 Annual Meeting of Stockholders virtually on May 6, 2026, with a record date of March 13, 2026 for voting eligibility. Additionally, Aptar plans to discuss its fourth-quarter and year-end 2025 results on a conference call on February 6, 2026.
Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment
AptarGroup, Inc. has achieved an "A List" ranking from the CDP for its leadership in climate change initiatives for the second consecutive year. This recognition highlights Aptar's efforts in cutting emissions, managing climate risks, and promoting a low-carbon economy. The company has set science-based targets for emissions reductions and improved its risk disclosures, demonstrating a strong commitment to environmental transparency and sustainability.
Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment
AptarGroup, Inc. has been recognized by the global environmental non-profit CDP with its prestigious "A List" score for climate change assessment for the second consecutive year. This recognition highlights Aptar's leadership in corporate environmental responsibility, including actions to cut emissions, mitigate climate risks, and further the low-carbon economy. The company has set science-based targets for emissions reductions and improved its risk and opportunities disclosures in line with TCFD recommendations.
Is the Options Market Predicting a Spike in AptarGroup Stock?
The options market suggests a significant price movement for AptarGroup (ATR) stock, indicated by unusually high implied volatility, particularly for the Feb. 20, 2026 $160 Call. Despite this, analysts currently rate AptarGroup as a Zacks Rank #4 (Sell), with recent downward revisions to earnings estimates. This high implied volatility might attract options traders looking to sell premium.
Is the Options Market Predicting a Spike in AptarGroup Stock?
The options market is indicating a potential spike in AptarGroup (ATR) stock, with the Feb. 20, 2026 $160 Call showing high implied volatility. Despite this options activity, fundamental analysis from Zacks Investment Research rates AptarGroup as a Zacks Rank #4 (Sell) due to recent downward revisions in earnings estimates. This high implied volatility, coupled with a "Sell" rating, suggests a potential opportunity for options traders to sell premium, betting that the stock's movement will be less than the market expects.
Aptar’s nasal delivery solutions used in CastleVax COVID-19 vaccine trial
AptarGroup, Inc. announced that its LuerVax and Spray Divider nasal vaccine delivery solutions are being utilized in CastleVax’s Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine candidate. The study, involving approximately 200 U.S. adults, aims to assess the safety, tolerability, and immune response of the intranasal vaccine compared to an FDA-approved injectable mRNA vaccine, with a focus on mucosal immunity. AptarGroup, headquartered in Crystal Lake, Illinois, boasts a strong financial position with $3.66 billion in revenue and a 2.5% growth in the past twelve months, having consistently raised its dividend for 33 consecutive years.
Nasal COVID-19 vaccine trial uses Aptar devices to test immunity levels
AptarGroup, Inc. announced that its nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being used in CastleVax's Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine candidate. This study will assess the vaccine's safety, tolerability, and systemic and mucosal immune response in approximately 200 U.S. adults. Aptar Pharma is supporting this trial with its expertise in regulatory pathways, technical support, and innovative device design to advance next-generation vaccine development.
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
AptarGroup, Inc. announced that its LuerVax® and Spray Divider™ nasal vaccine delivery solutions are being used in CastleVax’s Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine candidate. This trial will assess the safety, tolerability, and immune response of the intranasal vaccine compared to an FDA-approved injectable mRNA vaccine in around 200 U.S. adults. Aptar's involvement highlights its commitment to advancing vaccine delivery technologies and its role as a key partner in developing novel immunization strategies.
Aptar’s nasal delivery solutions used in CastleVax COVID-19 vaccine trial
AptarGroup's LuerVax and Spray Divider nasal vaccine delivery solutions are being utilized in CastleVax's Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine. The study aims to evaluate the safety, tolerability, and immune response of the intranasal vaccine compared to an FDA-approved injectable mRNA vaccine, focusing on mucosal immunity in approximately 200 U.S. adults. AptarGroup, with a market cap of $8.1 billion and a history of 33 consecutive years of dividend increases, continues to expand its market presence and product offerings, as highlighted by recent FDA approvals and strategic acquisitions.
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
AptarGroup, Inc. announced that its LuerVax® and Spray Divider™ nasal vaccine delivery solutions are being used in CastleVax's Phase II clinical trial for CVAX-01, an intranasal COVID-19 vaccine candidate. This collaboration highlights Aptar Pharma's role in advancing vaccine delivery technologies and supporting novel immunization strategies. The study aims to evaluate the safety, tolerability, and immune response of the intranasal vaccine in approximately 200 U.S. adults.
Aptar's Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink
AptarGroup, Inc. has announced its expanded portfolio of eye care solutions, prominently featuring its new "Beat the Blink" technology. This innovative delivery system is designed to enhance dosing precision and patient experience by mitigating the natural blink reflex, and is currently in an exclusive partnership with Bausch and Lomb. Aptar's offerings also include preservative-free multi-dose systems like the Ophthalmic Squeeze Dispenser and Advanced Preservative Free pumps, alongside digital healthcare solutions, all aimed at improving safe and precise ophthalmic drug delivery.
AptarGroup Unveils Innovative Eye Drop Delivery System in Strategic Partnership
AptarGroup, Inc. has introduced an innovative ophthalmic drug delivery system called "Beat the Blink™" in collaboration with Bausch + Lomb, aiming to improve dosing accuracy and patient adherence. This launch is part of Aptar's broader strategy to diversify revenue streams and increase investment in medically-focused, data-driven delivery systems, especially as the company anticipates a decline in emergency medicine-related revenue for fiscal 2026. The company is set to present this technology and its strategy at the J.P. Morgan Healthcare Conference, with investors keenly awaiting details on commercialization timelines and margin projections.
Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™
AptarGroup, Inc. has announced its expanding portfolio of eye care solutions, highlighted by their new technology, Beat the Blink™, developed to enhance dosing precision and patient experience by bypassing the blink reflex. This technology, currently in an exclusive partnership with Bausch and Lomb, aims to provide horizontal drop delivery and is designed for preservative-free formulations. Additionally, Aptar showcased its Ophthalmic Squeeze Dispenser (OSD), APF Advanced Preservative Free systems, and digital healthcare solutions, emphasizing their commitment to innovative and safe ophthalmic drug delivery.
Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™
AptarGroup, Inc. unveiled its latest eye care solution, Beat the Blink™, marking a significant advancement in ophthalmic drug delivery. This new technology, currently in an exclusive partnership with Bausch and Lomb, aims to enhance dosing precision and patient experience by mitigating the blink reflex. Aptar also highlighted its broader portfolio of eye care innovations, including the Ophthalmic Squeeze Dispenser and Advanced Preservative Free systems, all designed to meet evolving needs in both prescription and over-the-counter treatments.
Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink
AptarGroup, Inc. announced its expanded portfolio of eye care solutions, highlighted by their new "Beat the Blink" technology, designed to improve dosing precision and patient experience by overcoming the blink reflex. This technology, currently in exclusive partnership with Bausch and Lomb, aims to provide horizontal drop delivery, formula protection for preservative-free formulations, and ensure regulatory compliance. Aptar also detailed its Ophthalmic Squeeze Dispenser (OSD) for preservative-free multidose applications and its Advanced Preservative Free (APF) systems for various uses.
KeyBanc reiterates Overweight rating on AptarGroup stock at $220
KeyBanc has reiterated an Overweight rating on AptarGroup (NYSE:ATR) with a price target of $220, representing nearly 80% upside from its current price. The positive outlook is primarily driven by AptarGroup's dominant market share in intranasal delivery systems and the projected 14.1% annual growth in intranasal medicines through 2030. The firm also notes the company's attractive valuation compared to peers and its low price volatility.
KeyBanc reiterates Overweight rating on AptarGroup stock at $220
KeyBanc has reiterated an Overweight rating and a $220 price target for AptarGroup (NYSE:ATR), citing strong growth prospects in the intranasal drug delivery market where AptarGroup holds a 90% market share. The firm projects significant growth in core pharmaceutical business, especially with recent FDA approvals of intranasal drugs, and notes AptarGroup's life science business is undervalued compared to peers. The company has also recently announced new FDA-approved product use, a strategic acquisition, and a digital health partnership.
